TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: prevalence of medical or non-medical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPD diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % nodules with greater than 50% base volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: % patients free of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Radiographic whole defect depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Enrolled With a Partner
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Requiring Rescue With Corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Deviation From the Protocol Prescribed Steroid Tapering Regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Progression-free Survival (rPFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immune Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metastatic response assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of R1 cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Deceased
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent Clostridium difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: pathologic complete response (pathCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinically significant change in angina-frequency score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intervention Compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time of respiratory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Earlier weaning from oxygen support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Success of the face transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in psychopathology symptoms on PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in depressive symptoms on HAMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EPAO score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to patient exit (withdrawal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Therapist adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Concentration of NSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bispectral profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Nights Wet Per 2 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Abundance of Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of respiratory depression events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of CPG-consistent care of fever and neutropenia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of CPG-consistent care of chemotherapy induced nausea and vomiting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of CPG-consistent care of fertility preservation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in seizure severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: composite of major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: composite of any bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Assess severity of flu symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childhood Autism Rating Scale version 2 (CARS2)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the curve above baseline of ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum change from baseline in absolute neutrophil count (ANC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the serum concentration-time curve (AUC0-inf) of Pegfilgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of pegfilgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Anesthesia Emergence Delirium (PAED) Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Reported frequencies of unsafe storage of opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Reported frequencies of unsafe use of opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Reported frequencies of unsafe disposal of opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of seroconversion in HPV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 24 Hour Mean Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accessibility and feasibility of integrating predictive genomics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Amount of Hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of glycemic values in the A and B zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention failure of HBV transmission
Endpoint domain: Adverse events/effects
Primary endpoint: Total xenoestrogen burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BORG Dyspnoea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life SF-36 and EQ-5D
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 18F-MK-6240 binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary angiography Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: tDCS tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wolf Motor Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RPF to L-NMMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Corsi Task Block Span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Corsi Task Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rates of psychotropic drug prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of fever-relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the sores of breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of the area of the breast masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IBS-SSS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Impaired lower-extremity Selective Voluntary Motor Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Edinburgh Visual Gait Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Major Abdominal Complication (MAC)
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IFN-g (Interferon gamma) EliSpot cellular responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Infectious Postoperative Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of BMS-986195
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance to artesunate-amodiaquine combination therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: motion sickness severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0-3h Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Trough FEV1 Response (Change From Baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: St. George's Respiratory Questionnaire (SGRQ) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety (adverse Events and Serious Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of hemodynamic significant arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of non-hypoxic apnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Global Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immunoglobulin titres in bronchoalveolar fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptability (e.g. pain) of an injection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events after an injection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Liver Cancer Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of Subjects Who Had Adverse Events With the Swedish Adjustable Gastric Band (SAGB)
Endpoint domain: Adverse events/effects
Primary endpoint: Gross Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ER use or hospitalization for COPD
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: timing of cancer-related care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of cancer-related care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of entinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Percent Diameter Stenosis of the Culprit Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cohen's Kappa statistic (κ)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Positive and Negative Syndrome Scale (PANSS) - Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy measured by spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stimulant drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DIBELS test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of virus inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relief of osteoarthritis signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apical descensus relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in maximal power output during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (Area under the Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax (maximum plasma concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tissutal oximetry average value of the flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Domain specific energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postprandial serum triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in postprandial serum glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Positive and Negative Affect Schedule (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Depression Anxiety and Stress Scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in A clinically useful depression outcome scale (CUDOS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With an Serum Bactericidal Assay (SBA) Using Human Complement (SBA-HC) Titer ≥1:8 and ≥1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With SBA-HC Pre-booster Titer ≥1:8 Who Then Achieved ≥4-Fold Rise in SBA-HC Titer After Booster Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With SBA-HC Pre-vaccination Titer ≥1:8 Who Then Achieved ≥4-fold Rise in SBA-HC Titer After Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: One grade improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to the last measurable plasma concentration of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EORTC QLQ-C30 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EORTC QLQ-HCC18
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in peripheral systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numeric Rating Scale (NRS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tpCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parodontal disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Reduction in GERD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Successful Radial Arterial Catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of patients with no abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With a New Onset of Related Chronic Medical Condition
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Clinical Response (Defined as no Recurrence of Clostridium Difficile-Associated Diarrhea (CDAD))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: red cells counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: white cells counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: platlet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Yearly rate of hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Sessions Attended by Participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CTAS level assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between mitochondrial DNA content and number of mitochondria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation between mitochondrial DNA content and metabolic turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemically-confirmed 7-Day Point Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Efficiency (%)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rate of Cesarean Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline evaluation of static balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Lower Urinary Tract Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean diurnal IOP reduction of greater than or equal to 20% at month 12 vs baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time between apnoea and issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with confirmed inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall treatment-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Level of adherence to the program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sensitivity of CareStart™ G6PD rapid test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of CareStart™ G6PD rapid test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Monetary Incentive Delay task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident diagnosis of major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Medication Level Variability Index (MLVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Richness and evenness of microbial flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Hepatic Venous Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline HAD scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of AKI following LVAD or TAH implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Marinoff Dyspareunia Scale Score (MDSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Index of AUD recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Composite T-Score of MCI related neurocognitive measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Range of motion of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee score (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: changes in myocardial metabolic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Bacterial load after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Perceived stress change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in levels of Insulin-like growth factor-binding protein 1 (IGFBP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of Adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse medical events
Endpoint domain: Adverse events/effects